FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281682613> ?p ?o ?g. }

• W4281682613 endingPage "e056374" @default.
• W4281682613 startingPage "e056374" @default.
• W4281682613 abstract "It is currently unclear which cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, combined with endocrine therapy, is the preferred treatment approach in patients with hormone receptor (HR)-positive, human epidermal receptor-2 (HER2) negative metastatic breast cancer. The aim of this study was to evaluate the existing evidence for the comparative efficacy, safety and cost-effectiveness of different CDK4/6 inhibitors for metastatic breast cancer in first-line and second-line settings.We will systematically conduct a literature search in Embase, PubMed and the Cochrane Library and additional searches by handsearching citations of previous systematic reviews. We will also screen major conference proceedings (American Society of Clinical Oncology, European Society of Medical Oncology and San Antonio Breast Cancer Symposium). Preliminary scoping searches were conducted in July 2021, but the search will be updated when new trials are available. The primary outcome was progression-free survival. The secondary outcomes were overall survival, objective response rates, grade 3-4 haematological and non-haematological toxicities, quality-adjusted life years and incremental cost-effectiveness ratios. The risk of bias will be assessed by Cochrane risk of bias tools, and the quality of evidence will be assessed by the Grading of Recommendations Assessment, Development and Evaluation. Subgroup analyses and sensitivity analyses will be performed to further confirm our findings. In addition, one-way sensitivity analysis and probabilistic sensitivity analyses will be conducted to determine uncertainty.This study does not require ethics approval as only secondary data will be collected. The results of our study will provide an overview of the current level of CDK4/6 inhibitors for patients with HR-positive, HER2-negative metastatic breast cancer, and undertake subgroup analyses to explore variables that might affect these effects. The results of this study will be presented at an international clinical conference and published in a peer-reviewed journal.CRD42021266597." @default.
• W4281682613 created "2022-06-13" @default.
• W4281682613 creator A5010490147 @default.
• W4281682613 creator A5054927824 @default.
• W4281682613 creator A5064258102 @default.
• W4281682613 creator A5089408812 @default.
• W4281682613 date "2022-05-01" @default.
• W4281682613 modified "2023-10-11" @default.
• W4281682613 title "Role of CDK4/6 inhibitors in patients with hormone receptor (HR)-positive, human epidermal receptor-2 negative (HER-2) metastatic breast cancer study protocol for a systematic review, network meta-analysis and cost-effectiveness analysis" @default.
• W4281682613 cites W1503137832 @default.
• W4281682613 cites W1961026612 @default.
• W4281682613 cites W2010699829 @default.
• W4281682613 cites W2017019559 @default.
• W4281682613 cites W2035751279 @default.
• W4281682613 cites W2046024621 @default.
• W4281682613 cites W2057272791 @default.
• W4281682613 cites W2057550630 @default.
• W4281682613 cites W2083296039 @default.
• W4281682613 cites W2085803274 @default.
• W4281682613 cites W2098923148 @default.
• W4281682613 cites W2104675861 @default.
• W4281682613 cites W2106715003 @default.
• W4281682613 cites W2109051507 @default.
• W4281682613 cites W2121288264 @default.
• W4281682613 cites W2130048482 @default.
• W4281682613 cites W2131994307 @default.
• W4281682613 cites W2143025931 @default.
• W4281682613 cites W2144625636 @default.
• W4281682613 cites W2148345265 @default.
• W4281682613 cites W2149012794 @default.
• W4281682613 cites W2156098321 @default.
• W4281682613 cites W2157823046 @default.
• W4281682613 cites W2161374186 @default.
• W4281682613 cites W2164168324 @default.
• W4281682613 cites W246286872 @default.
• W4281682613 cites W2519603001 @default.
• W4281682613 cites W2528767298 @default.
• W4281682613 cites W2560635244 @default.
• W4281682613 cites W2588681363 @default.
• W4281682613 cites W2620993107 @default.
• W4281682613 cites W2737256970 @default.
• W4281682613 cites W2802776309 @default.
• W4281682613 cites W2804105316 @default.
• W4281682613 cites W2896846857 @default.
• W4281682613 cites W2916841405 @default.
• W4281682613 cites W2921747660 @default.
• W4281682613 cites W2921802707 @default.
• W4281682613 cites W2931385471 @default.
• W4281682613 cites W2972049666 @default.
• W4281682613 cites W2972248195 @default.
• W4281682613 cites W2976415870 @default.
• W4281682613 cites W2981795130 @default.
• W4281682613 cites W2995593755 @default.
• W4281682613 cites W3010197652 @default.
• W4281682613 cites W3035469000 @default.
• W4281682613 cites W3037927110 @default.
• W4281682613 cites W3043082495 @default.
• W4281682613 cites W3044961644 @default.
• W4281682613 cites W3049702673 @default.
• W4281682613 cites W3081949673 @default.
• W4281682613 cites W3089991573 @default.
• W4281682613 cites W3093527665 @default.
• W4281682613 cites W3104936322 @default.
• W4281682613 cites W3112668004 @default.
• W4281682613 cites W3127612182 @default.
• W4281682613 cites W3128646645 @default.
• W4281682613 cites W3129342924 @default.
• W4281682613 cites W3133509869 @default.
• W4281682613 cites W3154567952 @default.
• W4281682613 cites W3160834872 @default.
• W4281682613 cites W3164860903 @default.
• W4281682613 cites W3166403155 @default.
• W4281682613 cites W3169437264 @default.
• W4281682613 cites W3170157997 @default.
• W4281682613 cites W3189200395 @default.
• W4281682613 cites W4205724345 @default.
• W4281682613 cites W4206666777 @default.
• W4281682613 cites W4214525801 @default.
• W4281682613 cites W4231598961 @default.
• W4281682613 cites W4294215472 @default.
• W4281682613 doi "https://doi.org/10.1136/bmjopen-2021-056374" @default.
• W4281682613 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35636793" @default.
• W4281682613 hasPublicationYear "2022" @default.
• W4281682613 type Work @default.
• W4281682613 citedByCount "3" @default.
• W4281682613 countsByYear W42816826132022 @default.
• W4281682613 countsByYear W42816826132023 @default.
• W4281682613 crossrefType "journal-article" @default.
• W4281682613 hasAuthorship W4281682613A5010490147 @default.
• W4281682613 hasAuthorship W4281682613A5054927824 @default.
• W4281682613 hasAuthorship W4281682613A5064258102 @default.
• W4281682613 hasAuthorship W4281682613A5089408812 @default.
• W4281682613 hasBestOaLocation W42816826131 @default.
• W4281682613 hasConcept C121608353 @default.
• W4281682613 hasConcept C126322002 @default.
• W4281682613 hasConcept C143998085 @default.
• W4281682613 hasConcept C17744445 @default.
• W4281682613 hasConcept C189708586 @default.

• next